SCHEDULE 13G/A: Investment Funds Disclose 6.2% Stake in Petros Pharmaceuticals

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have disclosed a combined beneficial ownership of 6.2% in Petros Pharmaceuticals, Inc. common stock as of December 31, 2024.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Petros Pharmaceuticals, Inc.
• The Reporting Persons collectively beneficially own 657,614 shares of Petros Pharmaceuticals, Inc. common stock.
• This ownership represents 6.2% of the Issuer's common stock.
• The shares are issuable upon the exercise of certain warrants and conversion of convertible preferred stock.
• The issuable shares are subject to a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 10,014,872 shares of Common Stock outstanding as of November 12, 2024, as reported in the Issuer's Form 10-Q filed on November 13, 2024, plus the 657,614 shares held by the Reporting Persons.
• Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, a Cayman Islands exempted company, is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company, serves as the investment manager.
• Waqas Khatri serves as the managing member of Ayrton Capital LLC and is also a director of Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter the company's perceived value or outlook. It is neutral in sentiment.

Positives

• A significant institutional stake of 6.2% is held by the Reporting Persons, indicating investor interest in Petros Pharmaceuticals.

Future Outlook

The document is a beneficial ownership report and does not contain any forward-looking statements or guidance from Petros Pharmaceuticals, Inc. or the Reporting Persons regarding the Issuer's future performance or strategy.

Industry Context

This filing is a routine disclosure of a significant ownership stake by investment funds in a publicly traded pharmaceutical company. It reflects standard investment activity rather than specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may provide some confidence or signal continued investor interest in Petros Pharmaceuticals, Inc.

Key Dates

Keywords

Petros Pharmaceuticals, Common Stock, Schedule 13G, Beneficial Ownership, Ayrton Capital LLC, Alto Opportunity Master Fund, Waqas Khatri, Warrants, Convertible Preferred Stock, SEC Filing